Nov 4, 2021 8:00 am EDT Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
Oct 25, 2021 8:00 am EDT Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA
Jul 19, 2021 7:00 am EDT Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
Jun 15, 2021 8:00 am EDT Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
May 25, 2021 9:03 am EDT Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia